Advertisement

IR Playbook pp 419-427 | Cite as

Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Portal Hypertension

  • Rohit Koppula
  • Ziv J Haskal
Chapter

Abstract

Chronic liver disease results in approximately 38,000 deaths a year, making it the 12th leading cause of mortality in the United States. Progressive liver disease results in portal hypertension, which leads to sequelae such as ascites, variceal hemorrhage, hepatic hydrothorax, and hepatorenal syndrome. Management includes screening for esophageal varices and treating complications of portal hypertension with medical, endoscopic, and interventional therapies. The transjugular intrahepatic portosystemic shunt (TIPS) has been proven effective in treating variceal hemorrhage, refractory ascites, and other manifestations of portal hypertension. Clinical indications, patient selection, technical considerations, post-procedure management, and complications are discussed in this chapter.

Keywords

Portal hypertension Transjugular intrahepatic portosystemic shunt (TIPS) Esophageal varices Ascites Budd-Chiari Cirrhosis Variceal hemorrhage 

References

  1. 1.
    CDCData [Internet]. [cited 2017 Feb 3]. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_04.pdf.
  2. 2.
    Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7(2):141–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology (Baltimore, MD). 2004;39(2):280–2.CrossRefGoogle Scholar
  4. 4.
    Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology (Baltimore, MD). 1985;5(3):419–24.CrossRefGoogle Scholar
  5. 5.
    Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology. 1992;102(3):973–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Berzigotti A, Rossi V, Tiani C, Pierpaoli L, Zappoli P, Riili A, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol. 2011;46(5):687–95.CrossRefPubMedGoogle Scholar
  7. 7.
    Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (Baltimore, MD). 2000;31(2):324–9.CrossRefGoogle Scholar
  8. 8.
    Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353(21):2254–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin N Am. 1992;21(1):1–14.Google Scholar
  10. 10.
    Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Clin Liver Dis. 1997;1(1):1–12.CrossRefPubMedGoogle Scholar
  11. 11.
    García-Pagán J-C, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57(2):458–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology (Baltimore, MD). 2006;43(2 Suppl 1):S121–31.CrossRefGoogle Scholar
  13. 13.
    Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology (Baltimore, MD). 1987;7(1):122–8.CrossRefGoogle Scholar
  14. 14.
    Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis. 1997;17(3):175–89.CrossRefPubMedGoogle Scholar
  15. 15.
    Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol. 2010;53(6):1135–45.CrossRefPubMedGoogle Scholar
  16. 16.
    AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf [Internet]. [cited 2017 Mar 1]. Available from: http://www.aasld.org/sites/default/files/guideline_documents/AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf.
  17. 17.
    Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin N Am. 1992;21(1):149–61.Google Scholar
  18. 18.
    Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology. 1982;82(5 Pt 1):968–73.PubMedGoogle Scholar
  19. 19.
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD. The practice guidelines Committee of the American Association for the study of liver diseases and the practice parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007;102(9):2086–102.CrossRefPubMedGoogle Scholar
  20. 20.
    Sharma M, Rameshbabu CS. Collateral pathways in portal hypertension. J Clin Exp Hepatol. 2012;2(4):338–52.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Rösch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology. 1969;92(5):1112–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol. 2002;37(5):703–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Patidar KR, Sydnor M, Sanyal AJ. Transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2014;18(4):853–76.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51(1):306.CrossRefPubMedGoogle Scholar
  27. 27.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (Baltimore, MD). 2000;31(4):864–71.CrossRefGoogle Scholar
  28. 28.
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology (Baltimore, MD). 2001;33(2):464–70.CrossRefGoogle Scholar
  29. 29.
    Singal AK, Kamath PS. Model for end-stage liver disease. J Clin Exp Hepatol. 2013;3(1):50–60.CrossRefPubMedGoogle Scholar
  30. 30.
    Ferral H. The evaluation of the patient undergoing an elective transjugular intrahepatic portosystemic shunt procedure. Semin Interv Radiol. 2005;22(4):266–70.CrossRefGoogle Scholar
  31. 31.
    Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology. 2004;231(1):231–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol. 2005;28(3):307–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Fidelman N, Kwan SW, LaBerge JM, Gordon RL, Ring EJ, Kerlan RK. The Transjugular intrahepatic portosystemic shunt: an update. Am J Roentgenol. 2012;199(4):746–55.CrossRefGoogle Scholar
  34. 34.
    Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26(6):943–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology. 2003;124(3):634–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135(3):808–15.CrossRefPubMedGoogle Scholar
  37. 37.
    Rössle M, Olschewski M, Siegerstetter V, Berger E, Kurz K, Grandt D. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery. 2004;135(4):394–403.CrossRefPubMedGoogle Scholar
  38. 38.
    Dariushnia SR, Haskal ZJ, Midia M, Martin LG, Walker TG, Kalva SP, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2016;27(1):1–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Madoff DC, Wallace MJ, Ahrar K, Saxon RR. TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. Radiogr Rev Publ Radiol Soc N Am Inc. 2004;24(1):21–36–37.Google Scholar
  40. 40.
    Madoff DC, Wallace MJ. Reduced stents and stent-grafts for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. Semin Interv Radiol. 2005;22(4):316–28.CrossRefGoogle Scholar
  41. 41.
    Ferenci P. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Weber CN, Nadolski GJ, White SB, Clark TWI, Mondschein JI, Stavropoulos SW, et al. Long-Term Patency and Clinical Analysis of Expanded Polytetrafluoroethylene-Covered Transjugular Intrahepatic Portosystemic Shunt Stent Grafts. J Vasc Interv Radiol JVIR. 2015;26(9):1257–1265; quiz 1265.CrossRefPubMedGoogle Scholar
  43. 43.
    Suhocki P, Lungren M, Kapoor B, Kim C. Transjugular intrahepatic portosystemic shunt complications: prevention and management. Semin Interv Radiol. 2015;32(2):123–32.CrossRefGoogle Scholar
  44. 44.
    Luca A, Miraglia R, Maruzzelli L, D’Amico M, Tuzzolino F. Early liver failure after transjugular intrahepatic portosystemic shunt in patients with cirrhosis with model for end-stage liver disease score of 12 or less: incidence, outcome, and prognostic factors. Radiology. 2016;280(2):622–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Chung H-H, Razavi MK, Sze DY, Frisoli JK, Kee ST, Dake MD, et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications? J Gastroenterol Hepatol. 2008;23(1):95–101.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Virginia, Department of Radiology and Medical ImagingCharlottesvilleUSA
  2. 2.University of Virginia School of Medicine, Department of Radiology and Medical Imaging, Interventional Radiology DivisionCharlottesvilleUSA

Personalised recommendations